Short answer:
There is no FDA‑approved generic version of Xarelto (rivaroxaban) in the United States yet. The main patents protecting the drug are expected to expire around 2028–2029, after which generic manufacturers can file applications. It usually takes 1–2 years for a generic to receive approval, so you can expect a U.S. generic launch mid‑2029 to early‑2030 if all goes as planned.
---
Why the delay?
| Factor | What it means for generics |
|--------|-----------------------------|
| Patent portfolio | Rivaroxaban is protected by several patents that cover the active ingredient, specific dosing regimens, formulation, and even the use for certain indications. The earliest of these patents is set to expire in 2028; others will lapse in 2029–2030. |
| Regulatory pathway | Even after patents expire, a generic manufacturer must file an ANDA (Abbreviated New Drug Application), conduct bioequivalence studies, and wait for FDA review. That process typically takes 12–18 months. |
| Market strategy | Some companies (e.g., LEO Pharma, Bayer, and others) have announced generic plans, but they will still wait until the relevant patents expire to avoid infringement. |
---
What’s happening in other markets?
| Region | Status of generic rivaroxaban |
|--------|------------------------------|
| Europe (EMA) | Generic rivaroxaban was approved by the EMA in late 2023 (via a “generic” dossier from LEO Pharma). Availability in the EU is already underway. |
| Canada (Health‑CAN) | The Canadian patent is also scheduled to expire in 2028, and a generic application is pending. |
| Australia (TGA) | Similar to the U.S., generic approval is expected after 2028. |
---
How to stay informed
1. FDA website – Check the Generic Drug User Fee Amendments section or search for “rivaroxaban” in the Drug Approval Packages.
2. FDA’s Orange Book – Shows the patent and exclusivity status for each drug.
3. Industry news – Companies filing generic applications often announce it via press releases (e.g., LEO Pharma, Bayer).
---
Bottom line
- U.S. generic launch: likely mid‑2029 to early‑2030.
- Europe and other regions: generics are already available or will be very soon (2023–2024).
If you’re currently on Xarelto and wondering about cost‑saving options, you can discuss with your prescriber whether a brand‑name alternative (like Apixaban or Dabigatran) might suit your needs until a generic becomes available.